论文部分内容阅读
目的观察来得时(甘精胰岛素)与那格列奈联合应用治疗门诊2型糖尿病的临床疗效。方法选择符合诊断标准的2型糖尿病患者68例,给予睡前注射来得时并三餐前口服那格列奈,观察12周,分别检测治疗前、后空腹血糖(FBG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1c)。结果治疗后1、2、4、8、12周的FBG、PBG、HbA1c均较治疗前显著降低(P<0.05),低血糖的发生率低。结论来得时联合应用那格列奈可更好的模拟生理性胰岛素分泌,有效降低血糖,不良反应少,病人依从性好。
Objective To observe the clinical effect of combination of insulin glargine and nateglinide in the treatment of outpatient type 2 diabetes mellitus. Methods Sixty-eight patients with type 2 diabetes mellitus who met the diagnostic criteria were enrolled in this study. Before nocturnal injection, they were given nateglinide orally before meals and for 12 weeks. Fasting blood glucose (FBG), postprandial blood glucose PBG), glycated hemoglobin (HbA1c). Results The FBG, PBG and HbA1c at 1, 2, 4, 8 and 12 weeks after treatment were significantly lower than those before treatment (P <0.05), and the incidence of hypoglycemia was low. Conclusions The combination of nateglinide may be used to better simulate physiological insulin secretion and reduce blood sugar effectively with less adverse reactions and good patient compliance.